TABLE 2.
Comparison of the new recombinant IgG line blot assay with the previous recombinant IgG Western blot and line blot assays using the same antigens as in the recombinant IgG blot assay
| Groupa | No. of sera | No. (%) of positive sera in assay |
||
|---|---|---|---|---|
| Western blot | Line blotb | Line blot with additional antigens | ||
| EM | 15 | 5 (33.3) | 7 (46.7) | 8 (53.3) |
| NB | 50 | 36 (72.0) | 43 (86.0) | 44 (88.0) |
| ACA | 10 | 9 (90.0) | 10 (100.0) | 10 (100.0) |
| AT | 10 | 10 (100.0) | 9 (90.0) | 10 (100.0) |
| All LB cases | 85 | 60 (70.6) | 69 (81.2) | 72 (84.7) |
| Controls | 110 | 1 (0.9) | 0 (0.0) | 1 (0.9) |
a
EM, erythema migrans; NB, neuroborreliosis (stage II); ACA, acrodermatitis chronica atrophicans (stage III); AT, Lyme arthritis (stage III); all LB cases, Lyme borreliosis. Controls were blood donors (n = 60), patients with syphilis (n = 10), patients with positive rheumatoid factor (n = 10), and patients with fever of unknown origin (n = 30).
b
Using only antigens already evaluated in the previous recombinant IgG Western blot assay.